These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17695434)

  • 1. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
    Tubiana-Hulin M; Becette V; Bieche I; Mauriac L; Romieu G; Bibeau F; Macgrogan G; Bourgeois H; Chollet P; Defrance R; Spyratos F
    Anticancer Res; 2007; 27(4C):2689-96. PubMed ID: 17695434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
    Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
    Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03).
    Takei H; Suemasu K; Inoue K; Saito T; Okubo K; Koh J; Sato K; Tsuda H; Kurosumi M; Tabei T;
    Breast Cancer Res Treat; 2008 Jan; 107(1):87-94. PubMed ID: 18043897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
    Mlineritsch B; Tausch C; Singer C; Luschin-Ebengreuth G; Jakesz R; Ploner F; Stierer M; Melbinger E; Menzel C; Urbania A; Fridrik M; Steger G; Wohlmuth P; Gnant M; Greil R;
    Breast Cancer Res Treat; 2008 Nov; 112(1):203-13. PubMed ID: 18158620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
    Semiglazov VF; Semiglazov VV; Dashian GA; Zhil'tsova EK; Ivanov VG; Bozhok AA; Tonuzov EE; Paltuev RM; Mel'nikova OA; Klettsel' AA; Krivorot'ko PV; Donskikh RV; Kochetova IA; Damenia AO; Zernov KIu; Voskresenskiĭ DA; Bershteĭn LM
    Vopr Onkol; 2007; 53(4):400-8. PubMed ID: 17969401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
    Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
    Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Yiu CC; Chanplakorn N; Chan MS; Loo WT; Chow LW; Toi M; Sasano H
    Anticancer Res; 2010 Sep; 30(9):3465-72. PubMed ID: 20944124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
    Ueno T; Masuda N; Yamanaka T; Saji S; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Sasano H; Toi M
    Int J Clin Oncol; 2014 Aug; 19(4):607-13. PubMed ID: 24101215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
    Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
    Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
    Oduwole OO; Li Y; Isomaa VV; Mäntyniemi A; Pulkka AE; Soini Y; Vihko PT
    Cancer Res; 2004 Oct; 64(20):7604-9. PubMed ID: 15492288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
    Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
    Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.